A CEO's primary role differs fundamentally based on company type. In an asset-centric biotech, the CEO must act as a hands-on program manager, micromanaging execution. In a platform company, the CEO must be deeply embedded in the science to predict and leverage the technology's long-term trajectory.

The default rush to hire a C-suite is often a mistake. Luba Greenwood argues that a full-time CFO is an expensive and frequently unnecessary hire for an early-stage company. The role is only critical for complex, multi-asset companies or those actively pursuing an IPO.

The biggest skill gap for product leaders moving into the C-suite is financial literacy. Understanding P&Ls, investment models (VC, PE, public), and key business metrics is non-negotiable for effective business leadership at the CPO level, often more critical than deep product skills.

The ultimate differentiator for CEOs over decades isn't just product, but their skill as a capital allocator. Once a company generates cash, the CEO's job shifts to investing it wisely through M&A, R&D, and buybacks, a skill few are trained for but the best master.

The 'mini CEO' title isn't about power; it’s about responsibility for a product's financial success. To be effective, leaders must understand cost-to-serve, gross margin, and other financial metrics to make sound business decisions and speak the language of the board.

Recognizing that business leaders—not scientists—often set research priorities, Jonathan Steckbeck intentionally earned an MBA before his PhD. This nontraditional path gave him the commercial acumen to found a company where he could direct both the scientific and business strategy from day one.

The transition from a resource-rich environment like Novartis to an early-stage biotech reveals a stark contrast. The unlimited access to a global organization is replaced by a total reliance on a small, nimble team where everyone must be multi-skilled and hands-on, a change even experienced executives find jarring.

Unlike software startups that can "fail fast" and pivot cheaply, a single biotech clinical program costs tens of millions. This high cost of failure means the industry values experienced founders who have learned from past mistakes, a direct contrast to Silicon Valley's youth-centric culture.

Investor preference for CEOs has shifted dramatically. While 2019-2021 favored scientific founder-CEOs, today’s tough market demands leaders with prior CEO experience. The ideal candidate has a "matrix organization" background, understanding all business functions, not just the science.